Drug Trial Radar · NCT04203485
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: May 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
762
Planned (sponsor's estimate)
Start
Jun 15, 2020
Primary completion
Mar 31, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.
Conditions
- PD-L1 Positive Non-small Cell Lung Cancer
Interventions
Camrelizumab 200mgBiological
Camrelizumab 200mg q2w ivgtt
Apatinib Mesylate 250mgDrug
Apatinib Mesylate 250mg po qd
Pemetrexed disodium for injectionDrug
Pemetrexed disodium for injection 500 mg/m2 q3w
Paclitaxel injectionDrug
Paclitaxel injection 175 mg/m2 q3w
CarboplatinDrug
Carboplatin AUC 5 mg/mL/min q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) assessed by Independent review committee (IRC)Time frame: up to 2 years
- Overall survivalTime frame: up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.